PMID- 37151285
OWN - NLM
STAT- MEDLINE
DCOM- 20230509
LR  - 20230517
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 11
DP  - 2023
TI  - Somatic mutation profiling, tumor-infiltrating leukocytes, tertiary lymphoid 
      structures and PD-L1 protein expression in HER2-amplified colorectal cancer.
PG  - e15261
LID - 10.7717/peerj.15261 [doi]
LID - e15261
AB  - The status of human epidermal growth factor receptor 2 (HER2) for the prognosis 
      in colorectal cancer (CRC) is controversial, and the characteristics of the 
      somatic mutation spectrum, tumor-infiltrating leukocytes, tertiary lymphoid 
      structures and PD-L1 protein are unknown in HER2-amplified colorectal cancer 
      (HACC). In order to explore these characteristics along with their correlation 
      with clinicopathological factors and prognosis in HACC. Samples of 812 CRC 
      patients was collected. After immunohistochemistry (IHC), 59 of 812 were found to 
      be HER2-positive, then 26 of 59 samples were further determined to be HER2 
      amplification by fluorescence in situ hybridization (FISH). Somatic mutation 
      profiling of HACC was analysed using whole exome sequencing (WES). Multiplex 
      fluorescence immunohistochemistry (mIHC) was used for tumor-infiltrating 
      leukocytes and tertiary lymphoid structures (TLSs), while PD-L1 protein was 
      detected by IHC. Our results indicate that the detection rates of HER2 positivity 
      by IHC and FISH were 7.3% and 3.2% respectively, and HER2 amplification is 
      correlated with distant tumour metastasis. The somatic mutation profiling 
      revealed no differences between HACC and HER2-negative CRC. However, TP 53 
      strongly correlated with poor prognosis in HACC. Furthermore, tumor-infiltrating 
      T cells and TLSs in the tumor immune microenvironment, as well as PD-L1 
      expression, were higher in HACC than in HER2-negative controls. However, none of 
      them were associated with the prognosis of HACC. In all, HER2 amplification is 
      correlated with distant metastasis and TP53 gene mutation may be a potential 
      protective mechanism of HACC.
CI  - (c)2023 Liu et al.
FAU - Liu, Xiao-Ting
AU  - Liu XT
AD  - Department of Oncology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, China.
FAU - Kou, Zhi-Yong
AU  - Kou ZY
AD  - Department of Oncology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, China.
FAU - Zhang, Hushan
AU  - Zhang H
AD  - Zhaotong Healthy Vocational College, Zhaotong, Yunnan, China.
FAU - Dong, Jian
AU  - Dong J
AD  - Colorectal Cancer Clinical Research Center, Yunnan Cancer Hospital, Kunming, 
      Yunnan, China.
FAU - Zhang, Jian-Hua
AU  - Zhang JH
AD  - Department of General Surgery, The Third People's Hospital of Honghe Prefecture, 
      Honghe, Yunnan, China.
FAU - Peng, You-Jun
AU  - Peng YJ
AD  - Department of General Surgery, The Third People's Hospital of Honghe Prefecture, 
      Honghe, Yunnan, China.
FAU - Ma, Shu Min
AU  - Ma SM
AD  - Department of General Surgery, The Second People's Hospital of Qujing, Qujing, 
      Yunnan, China.
FAU - Liang, Lei
AU  - Liang L
AD  - Department of General Surgery, The Third People's Hospital of Honghe Prefecture, 
      Honghe, Yunnan, China.
FAU - Meng, Xuan-Yu
AU  - Meng XY
AD  - Department of Oncology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, China.
FAU - Zhou, Yuan
AU  - Zhou Y
AD  - Department of Oncology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, China.
FAU - Yang, Jun
AU  - Yang J
AD  - Department of Oncology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230502
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - 0 (B7-H1 Antigen)
SB  - IM
MH  - Humans
MH  - B7-H1 Antigen/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - *Tertiary Lymphoid Structures/genetics
MH  - *Colorectal Neoplasms/genetics
MH  - Mutation
MH  - Tumor Microenvironment
PMC - PMC10162038
OTO - NOTNLM
OT  - PD-L1 expression
OT  - Colorectal cancer
OT  - HER2
OT  - Somatic mutation profiling
OT  - Tumour immune microenvironment
COIS- The authors declare there are no competing interests.
EDAT- 2023/05/08 06:42
MHDA- 2023/05/09 10:16
PMCR- 2023/05/02
CRDT- 2023/05/08 03:47
PHST- 2023/01/12 00:00 [received]
PHST- 2023/03/28 00:00 [accepted]
PHST- 2023/05/09 10:16 [medline]
PHST- 2023/05/08 06:42 [pubmed]
PHST- 2023/05/08 03:47 [entrez]
PHST- 2023/05/02 00:00 [pmc-release]
AID - 15261 [pii]
AID - 10.7717/peerj.15261 [doi]
PST - epublish
SO  - PeerJ. 2023 May 2;11:e15261. doi: 10.7717/peerj.15261. eCollection 2023.